P. Steg

发表

Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort.

G. Lamas, G. Knatterud, W. Cantor, 2012, American heart journal.

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

E. Antman, J. Mega, B. Horne, 2017 .

Five-Year Survival in Patients With ST-Segment–Elevation Myocardial Infarction According to Modalities of Reperfusion Therapy: The French Registry on Acute ST-Elevation and Non–ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort

J. Ferrières, N. Danchin, T. Simon, 2014, Circulation.

Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.

S. Pocock, G. Stone, T. Henry, 2016, Journal of the American College of Cardiology.

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Braunwald, S. Normand, E. Braunwald, 2014, The New England journal of medicine.

Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis.

P. Serruys, G. Stone, A. Kastrati, 2016, JACC. Cardiovascular interventions.

Response to Letter Regarding Article, “Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern”

E. Camenzind, W. Wijns, P. Steg, 2007 .

Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials

M. Valgimigli, R. Stables, D. Erlinge, 2023, Circulation.

A Patient with Glanzmann Thrombasthenia and Epistaxis Successfully Treated with Recombinant Factor Vila

P. Steg, H. Benamer, P. Steg, 1996, Thrombosis and Haemostasis.

Underlying Causes of TIA and Minor Ischemic Stroke and Risk of Major Vascular Events.

P. Touboul, P. Amarenco, S. Uchiyama, 2023, JAMA neurology.

Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents.

L. Mauri, R. Yeh, P. Steg, 2015, The American journal of cardiology.

Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials.

P. Serruys, G. Stone, A. Kastrati, 2016, JACC. Cardiovascular interventions.

Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study

L. Mauri, R. Brindis, D. Kereiakes, 2016, Circulation.

Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.

G. Dangas, U. Baber, B. Vogel, 2024, American heart journal.

Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.

G. Dangas, G. Weisz, U. Baber, 2023, JACC. Cardiovascular interventions.

Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry.

S. Pocock, T. Henry, G. Dangas, 2017, International journal of cardiology.

Use of drug eluting stents: expert consensus of the French Society of Cardiology.

J. Ferrières, P. Steg, N. Danchin, 2008, Archives of cardiovascular diseases.

Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.

Samin K. Sharma, G. Dangas, S. Mehta, 2023, The American journal of cardiology.